Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds
Novartis is getting Tourmaline Bio’s pacibekitug, a Phase 3-ready antibody drug in development for atherosclerotic cardiovascular disease (ASCVD). Tourmaline licensed pacibekitug from Pfizer, which remains eligible for milestone payments tied to the progress of the drug.